1. Pink Sheet
  2. >>Pathways & Standards

Thinking Post-COVID: How Will US FDA Transition Drug, Vaccine EUAs To Full Approvals?

 
• By Derrick Gingery

Sponsors seek clarity about the transition process, which could last a year or longer.

Bike team pursuit
Many sponsors already are pursuing full approval of products now available through EUAs. • Source: Alamy

As calls increase to move beyond the coronavirus pandemic and return to normal life, sponsors are growing uneasy about the future of the drugs available under emergency use authorizations.

EUAs are intended to allow temporary use of a product during a public health emergency, but cannot remain available once...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.